Firefly Neuroscience (AIFF) Stock News, Mar 2025-Mar 2026

Firefly Neuroscience (NASDAQ: AIFF) reported Q3 2025 results showing significant integration benefits from its May 2025 acquisition of Evoke. Q3 revenue was $388,000, up from $33,000 year‑over‑year and +30% sequentially. EEG/ERP scan volumes rose 10.9% sequentially. Total operating expenses fell ~35% versus Q3 2024 to ~$2.8 million, helping reduce Q3 net loss to ~$2.6 million (‑38% year‑over‑year). Cash used in operations was ~$1.5 million (lowest quarter in first nine months of 2025) and the company ended the quarter with $4.3 million cash. The company also highlighted new CLEAR preprocessing technology and strategic partnerships advancing its EEG/ERP offerings.

Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with HealingMaps and Advanced Behavioral Strategies to provide EEG-based cognitive analytics to over 2,500 specialized clinics across North America. The collaboration follows HealingMaps' launch of the Healing Health Alliance, a pioneering Group Purchasing Organization for alternative therapy clinics.

The partnership will integrate Firefly's FDA-510(k)-cleared brain health analytics platform, which uses AI and EEG technology to provide objective assessments, replacing traditional subjective questionnaires. The platform analyzes brain activity using the world's largest normative EEG/ERP database, offering standardized insights for ketamine, psilocybin, and TMS treatments.

Firefly Neuroscience (NASDAQ: AIFF) has announced the successful deployment of its new 'CLEAR' (CLeaning EEG ARtifacts) Platform, powered by NVIDIA L40S GPU technology. The platform represents a significant advancement in EEG data preprocessing, achieving 60-80% faster processing times while maintaining high signal quality.

The CLEAR Platform utilizes state-of-the-art signal processing and machine learning techniques to clean EEG recordings from various artifacts, including muscle activity and environmental interference. This technology enhancement enables better detection of neural biomarkers crucial for neurological and psychiatric condition diagnosis and treatment.

This development follows Firefly's recent acceptance into the NVIDIA Connect Program and leverages the company's position as owner of the world's largest standardized EEG/ERP repository.

Firefly Neuroscience (NASDAQ: AIFF) has announced a new commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital to utilize its FDA-cleared BNA™ Platform in a groundbreaking neuroscience study. The research focuses on investigating the neurophysiological impact of 15q13.3 copy number variants (CNVs).

The study involves analyzing EEG data from 30 subjects (15 with deletions and 15 with duplications) using Firefly's technology through 2026. The company will provide EEG systems, training, and analytical support, comparing results to its proprietary FDA-cleared normative database.

This collaboration builds on previous work between Firefly and Prof. Dr. med. Christian Schaaf, including a joint publication on CHRNA7-related phenotypes, and represents an important step in Firefly's commercial licensing strategy.

Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, announced its upcoming addition to the Russell Microcap® Index effective June 30, 2025. This milestone comes less than a year after the company's Nasdaq listing via reverse merger. CEO Greg Lipschitz highlighted key 2025 achievements including: discovery of a cognitive brain age biomarker using their FDA-cleared BNA Platform, acceptance into NVIDIA Connect program, expansion through Evoke Neuroscience acquisition, and development of a method to distinguish between different stages of Alzheimer's. The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets, are widely used by investment managers and institutional investors. Membership in the Russell Microcap® Index lasts one year and includes automatic inclusion in corresponding growth and value style indexes.

Firefly Neuroscience (NASDAQ: AIFF) has made significant progress in Alzheimer's research, developing a method to differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia using EEG/ERP and volumetric MRI technology. The study showed that EEG measures alone achieved ~80% accuracy in categorizing cognitive conditions, while combining EEG with vMRI increased accuracy to ~87%. The research, conducted on real-world patients in memory clinics, identified three key EEG measures and left temporal lobe size as crucial predictors. This breakthrough builds upon Firefly's FDA-cleared BNA™ AI platform and recent Evoke acquisition, leveraging a database of over 180,000 standardized EEG/ERP assessment records. The company aims to develop a more accessible, cost-effective, and scalable approach to early Alzheimer's detection and staging.

Firefly Neuroscience (NASDAQ: AIFF) has acquired Evoke Neuroscience for $6 million, paid 50% in cash and 50% in common stock at $3.50 per share. The acquisition includes a potential $500,000 earn-out in stock if Evoke achieves $3 million in annualized revenues within three years.

The deal significantly expands Firefly's assets, including: a 2x increase in proprietary brain scans to over 180,000 EEG/ERP assessment records, a 3x expansion in granted patents to 27, and a 10x growth in commercial users to over 60. Evoke brings $30 million in historical revenues and extensive EEG/ERP electrophysiology data collection.

This acquisition, combined with Firefly's recent acceptance into the NVIDIA Connect program, advances the company's goal of developing the world's first EEG/ERP-based foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology.

Firefly Neuroscience (NASDAQ: AIFF) has acquired Evoke Neuroscience in a strategic move to enhance its brain health technology portfolio. The $6 million acquisition, paid 50% in cash and 50% in stock at $3.50 per share, includes a potential $500,000 earn-out. The deal significantly expands Firefly's assets with: over 180,000 standardized EEG/ERP assessment records (2x increase), 27 granted patents (3x increase), and 60+ commercial users (10x increase). Evoke brings 16 years of experience and $30 million in historical revenue. This acquisition strengthens Firefly's FDA-cleared Brain Network Analytics (BNA™) technology and advances their goal of developing the first EEG/ERP-based foundation model of the human brain, leveraging their recent acceptance into the NVIDIA Connect program.

Hemostemix (TSXV: HEM) and Firefly Neuroscience (NASDAQ: AIFF) have announced a collaboration to conduct a Phase 1 clinical trial studying ACP-01 as a treatment for vascular dementia. The trial will evaluate brain wave activity in up to 100 patients using Firefly's FDA-Cleared BNA™ platform.

The study will assess patients before treatment and at 3 and 6-month intervals post-treatment. Hemostemix will leverage Firefly's database of 77,000 EEG brain scans across twelve disorders. The trial's primary endpoints include safety assessment, ACP-01 delivery feasibility via intrathecal injection, dosage safety, and tolerability.

Secondary endpoints encompass cognitive functional assessment, clinical dementia rating, quality of life assessment, and MRI analyses of brain volume and blood flow. The exploratory endpoint will use Firefly's BNA™ readout at specified intervals to objectively evaluate ACP-01's efficacy in treating vascular dementia.